動物用炭疽ワクチンの世界市場規模：製品別、用途別、流通チャネル別、地域範囲別および予測

動物用炭疽ワクチンの市場規模と予測

動物用炭疽ワクチン市場規模は、2024年に91億4,000万米ドルと評価され、2026年から2032年の予測期間中にCAGR 10.6%で成長し、2032年には158億3,000万米ドルに達すると予測されます。

炭疽ワクチン産業規模の拡大は、R&D活動への投資増加、新規参入、製品革新、技術的ブレークスルー、効果的な資源配分、地域・顧客基盤拡大のためのライバル企業間競争の激化などに起因しています。近い将来、政府の政策やインセンティブ、有利な法規制が動物用炭疽ワクチン市場の成長を促進すると予想されます。可処分所得の増加に伴い顧客の消費力は拡大し、炭疽ワクチン市場の利益に貢献します。動物用炭疽ワクチンの世界市場レポートは市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

動物用炭疽ワクチンの世界市場促進要因

動物用炭疽ワクチン市場の市場促進要因は、様々な要因によって影響を受けます。これらには以下が含まれます：

• 炭疽菌発生件数の増加：多くの地域では、家畜や野生動物の集団における炭疽菌の発生頻度が依然として懸念されています。このため、家畜の間で炭疽病が蔓延するのを防ぎ、人間と家畜の健康を守るために、効率的なワクチン接種プログラムを策定し、実施する必要があります。
• 政府の取り組み炭疽病の発生を管理・予防するため、政府機関や獣医当局によるワクチン接種プログラムが頻繁に実施されています。ワクチンの生産、調達、研究開発に対する政府の投資は、炭疽ワクチン接種に対する獣医業界の需要を促進しています。
• 拡大する畜産業：世界の人口が増加するにつれて、肉、ミルク、皮革のような動物から生成される商品のニーズも増加します。畜産業の拡大により、疾病の発生から動物を守り、安定した安全な食料供給網を維持するために炭疽菌予防接種の必要性が高まっています。
• 知識と教育獣医の専門家や畜産農家が炭疽菌感染の危険性について知識を深めることにより、積極的な予防接種プログラムが奨励されています。炭疽菌の発生を食い止めるための予防接種の価値を強調する教育活動の結果、市場は拡大しています。
• 技術開発：より安全で効果的な炭疽菌ワクチンの開発は、バイオテクノロジーとワクチン製剤法の進歩によって可能となりました。アジュバントや革新的な送達方法によって免疫が拡大し、ワクチンの有効性が向上したため、獣医師によるワクチン接種率が向上しました。
• 世界化と貿易：規制を遵守し、貿易の継続性を維持するため、牛や畜産物の世界の流通量の増加に伴い、疾病の予防と管理がより重視されています。炭疽菌に対する予防接種プログラムは、このような条件を満たし、市場の需要を高めるために不可欠です。
• アウトブレイクへの備え炭疽菌は、特定の地政学的状況下で意図的に放出される可能性のある生物学的ハザードです。炭疽菌に対する予防接種は、バイオテロのリスクに対抗し、公衆衛生を守るための準備措置の一環として、政府や獣医機関が購入しています。

動物用炭疽ワクチンの世界市場抑制要因

いくつかの要因が動物用炭疽ワクチン市場の抑制要因または課題として作用する可能性があります。これらには以下が含まれます：

• 一部の分野における知識の制限：特にインフラや資源の乏しい貧困国では、炭疽菌やワクチン接種の価値に関する知識が十分でない場合があります。そのため、炭疽菌ワクチンの普及が妨げられ、特定地域での市場拡大が制限される可能性があります。
• 規制上の障害：動物用ワクチン接種の規制当局の認可には費用と時間がかかります。安全性、有効性、品質管理に関する規制が強化されれば、小規模なワクチン開発企業の市場参入が困難になり、競争や技術革新が制限される可能性があります。
• ワクチンの流通と保管の難しさ：炭疽菌ワクチンの有効性を維持するためには、冷蔵などの特別な保管環境が必要とされることが多いです。コールドチェーンのインフラが整備されていない地域では、ワクチンの適切な保管と配送を確保することは論理的に困難であり、ワクチン接種の有効性と入手のしやすさに影響を及ぼす可能性があります。
• リスクの低さの認識：畜産農家や獣医学の専門家は、炭疽菌の発生が稀であったり不定期であったりする地域では、炭疽菌に感染する可能性はほとんどないと考えているかもしれないです。このため、特に炭疽病がそれほど一般的でない場合には、人々は自己満足に陥り、炭疽病予防接種の需要が減少する可能性があります。
• コストの問題：炭疽病に対するワクチン接種に関する農家の決定は、ワクチン、ワクチン接種用品、獣医師のサービス費用など、ワクチン接種に関連する費用に影響される可能性があります。財政が乏しい地域や優先順位が相反する地域では、炭疽病予防接種の普遍的な受け入れが、費用対効果の認識によって妨げられる可能性があります。
• 有効性と防御期間：ワクチン技術は進歩したが、炭疽ワクチン接種による防御の有効性と持続性には疑問が残る。ブースター投与の必要性やワクチンの有効性のばらつきは、ワクチン接種率や市場におけるワクチンの一般的な人気に影響を与える可能性があります。
• 効果的なバイオセキュリティ対策：ワクチン接種プログラムに加え、牛群における炭疽菌の発生を予防することが重要です。不適切な死体処理や不適切な検疫プロトコルなど、不十分なバイオセキュリティ対策によって、予防接種キャンペーンの効果が損なわれる可能性があります。

目次

第1章 動物用炭疽ワクチンの世界市場導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 動物用炭疽ワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 動物用炭疽ワクチンの世界市場：製品別

• 概要
• 無細胞PAワクチン
• 生ワクチン

第6章 動物用炭疽ワクチンの世界市場：用途別

• 概要
• 動物用
• ヒト用

第7章 動物用炭疽ワクチンの世界市場：流通チャネル別

• 概要
• 病院薬局
• 小売薬局
• その他

第8章 動物用炭疽ワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の動物用炭疽ワクチン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第10章 企業プロファイル

• Ceva Sante Animale
• Bayer Sanidad Animal
• Central Veterinary Control and Research Institute
• Agrovet
• Colorado Serum Company
• Empresa Colombiana De Productos Veterinarios S.A.
• Biogenesis Bago SA
• Indian Immunologicals Limited
• Botswana Vaccine Institute
• Centro Diagnostico Veterinario

第11章 企業プロファイル付録

• 関連調査

Veterinary Anthrax Vaccines Market Size And Forecast

Veterinary Anthrax Vaccines Market size was valued at USD 9.14 Billion in 2024 and is projected to reach USD 15.83 Billion by 2032, growing at a CAGR of 10.6% during the forecasted period 2026 to 2032.

The increase in the size of the anthrax vaccines industry can be attributed to rising investments in R&D activities, the entry of new players, product innovation, technological breakthroughs, effective resource allocation, and growing competition among business rivals to expand its regional and customer base. Government policies and incentives, as well as favorable legislation, are expected to drive the growth of the Veterinary Anthrax Vaccines Market in the near future. Customers' spending power will expand as their disposable income rises, contributing to the market profits for anthrax vaccinations. The Global Veterinary Anthrax Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Veterinary Anthrax Vaccines Market Drivers

The market drivers for the Veterinary Anthrax Vaccines Market can be influenced by various factors. These may include:

• Rising Anthrax Incidences: In many areas, there is still concern over the frequency of anthrax in livestock and wildlife populations. This makes it necessary to create and implement efficient vaccination programmes in order to prevent the disease from spreading among animals and protect the health of both humans and animals.
• Government Initiatives: To manage and prevent anthrax outbreaks, vaccination programmes are frequently implemented by government agencies and veterinary authorities. Government investments in vaccine production, procurement, and research and development are what fuel the veterinary industry's demand for anthrax vaccinations.
• Expanding Livestock Industry: As the world's population rises, so does the need for goods generated from animals, like meat, milk, and leather. The necessity for anthrax vaccinations to safeguard animal populations against disease outbreaks and maintain a stable and secure food supply chain is increased by the expansion of the livestock industry.
• Knowledge and Education: Proactive immunisation programmes are encouraged by veterinary professionals and livestock farmers' heightened knowledge of the dangers of anthrax infection. The market is growing as a result of education initiatives emphasising the value of immunisation in halting anthrax outbreaks.
• Technological Developments: The development of safer and more effective anthrax vaccinations has been made possible by advances in biotechnology and vaccine formulation methods. Adjuvants and innovative delivery methods extend immunity and improve vaccine efficacy, which increases vaccination rates among veterinarians.
• Globalisation and Trade: In order to comply with regulations and maintain trade continuity, there is a greater emphasis on disease prevention and control as global traffic in cattle and animal products grows. Programmes for immunisation against anthrax are essential for fulfilling these conditions and increasing market demand.
• Preparedness for Outbreaks: Anthrax is still a biological hazard that might be intentionally released in specific geopolitical situations. Vaccinations against anthrax are purchased by governments and veterinary agencies as part of their readiness measures to counter bioterrorism risks and protect public health.

Global Veterinary Anthrax Vaccines Market Restraints

Several factors can act as restraints or challenges for the Veterinary Anthrax Vaccines Market. These may include:

• Limited Knowledge in Some Areas: There may not be enough knowledge about anthrax and the value of vaccination in some areas, especially in poor nations with little infrastructure and resources. This may prevent the spread of anthrax vaccinations and restrict market expansion in certain regions.
• Regulatory Obstacles: Veterinary vaccination regulatory clearances can be expensive and time-consuming. Stricter safety, efficacy, and quality control regulations could make it difficult for smaller vaccine developers to enter the market, which would limit competition and innovation.
• Difficulties with Vaccine Distribution and Storage: To preserve effectiveness, anthrax vaccinations frequently need particular storage settings, such as refrigeration. It can be logistically difficult to ensure appropriate vaccine storage and delivery in areas without cold chain infrastructure, which can affect vaccination efficacy and accessibility.
• Perceived Low Risk: Livestock farmers and veterinary experts may believe that there is little chance of contracting anthrax infection in areas where anthrax outbreaks are uncommon or irregular. This may cause people to become complacent and decrease the demand for anthrax vaccinations, especially when the disease is not as common.
• Cost Issues: Farmers' decisions on vaccination against anthrax may be influenced by costs associated with vaccination, including as the cost of vaccines, vaccination supplies, and veterinarian services. In areas where finances are scarce or priorities conflict, the universal acceptance of the anthrax immunisation may be hindered by its perceived cost-effectiveness.
• Efficacy and Duration of protection: Although vaccine technology has advanced, questions may still remain regarding the effectiveness and longevity of protection offered by anthrax vaccinations. The necessity for booster doses and variations in vaccine efficacy may have an effect on vaccination rates as well as the vaccine's general popularity in the market.
• Effective biosecurity measures: are crucial in preventing anthrax outbreaks in cattle herds, in addition to vaccination programmes. The efficacy of immunisation campaigns may be compromised by inadequate biosecurity measures, such as improper corpse disposal and inadequate quarantine protocols.

Global Veterinary Anthrax Vaccines Market: Segmentation Analysis

The Global Veterinary Anthrax Vaccines Market is Segmented on the basis of Product, Application, Distribution Channel, and Geography.

Veterinary Anthrax Vaccines Market, By Product

• Cell Free PA Vaccines
• Live Attenuated Vaccine

Based on Product, the market is segmented into Cell Free PA Vaccines and Live Attenuated Vaccine. The live vaccines category is expected to increase rapidly throughout the projected period. The live vaccination comprises spores from Bacillus anthracis attenuated strains, which are used to treat anthrax illness. Anthrax is produced by a big bacterium, and the major reason for anthrax immunization is the danger of inhalation infection. All animal vaccinations are live vaccines, and their use for human consumption necessitates a withholding period prior to slaughter.

Veterinary Anthrax Vaccines Market, By Application

• Animal Use
• Human Use

Based on Application, the market is segmented into Animal Use and Human Use. For the forecasted period, the animal usage sector is expected to lead the segment by application. Animals receive a large number of anthrax vaccinations. Anthrax is largely a herbivore disease. In veterinary medicine, a live unencapsulated version of B. anthracis and strain stern has been utilized to protect animals.

Veterinary Anthrax Vaccines Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Hospital pharmacies have dominated the market and are predicted to rise at a high rate throughout the forecasted period. The hospital pharmacies sector market share has been driven by a series of patients arriving at a hospital emergency department and anthrax vaccinations, which are usually offered in hospital pharmacies. Anthrax vaccinations are not communicable from person to person; nonetheless, typical hospital cleanliness measures must be followed for the therapy, which may only be administered in hospitals.

Veterinary Anthrax Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, the Global Veterinary Anthrax Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American area led the worldwide Veterinary Anthrax Vaccines Market, whereas the Asia Pacific is a fast-rising region. North America dominates the market as a result of government attempts to prevent the spread of anthrax and the existence of several ongoing programs under organizations such as HHS-CDC, BARDA, ASPR, NIAID, and the FDA that are supporting market growth. Asia Pacific is a rapidly rising region as R&D funding increases. Furthermore, the presence of advanced healthcare infrastructure in Japan, as well as broad vaccine manufacturing facilities, is propelling the market growth.

Key Players

The "Global Veterinary Anthrax Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Ceva Sante Animale, Bayer Sanidad Animal, Central Veterinary Control and Research Institute, Agrovet, Colorado Serum Company, Empresa Colombiana De Productos Veterinarios S.A., Biogenesis Bago SA, Indian Immunologicals Limited, Botswana Vaccine Institute, and Centro Diagnostico Veterinario.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In August 2020, Elusys Therapeutics Inc. (Elusys) received Health Canada clearance for Anthim (obiltoxaximab for injection), a monoclonal antibody (mAb) anthrax antitoxin for the treatment of anthrax inhalation. It can be used to treat post-exposure prophylaxis in both adults and children.
• In August 2020, Dr. Jamie Benn Felix and the Cook Wildlife Lab team from Texas A&M University College of Veterinary Medicine & Biomedical Sciences performed pilot research for the first oral anthrax vaccination for cattle (CVMBS).

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VETERINARY ANTHRAX VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VETERINARY ANTHRAX VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Cell Free PA Vaccines
• 5.3 Live Attenuated Vaccines

6 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Animal Use
• 6.3 Human Use

7 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Others

8 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL VETERINARY ANTHRAX VACCINES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Ceva Sante Animale
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Bayer Sanidad Animal
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Central Veterinary Control and Research Institute
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Agrovet
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Colorado Serum Company
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Empresa Colombiana De Productos Veterinarios S.A.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Biogenesis Bago SA
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Indian Immunologicals Limited
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Botswana Vaccine Institute
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Centro Diagnostico Veterinario
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research